arrow_back Civic Audit
Share share

Ending Tax Deductions for Direct-to-Consumer Drug Advertisements

This new bill aims to eliminate tax deductions for direct-to-consumer drug advertising expenses. This means pharmaceutical companies will no longer be able to reduce their taxes by deducting costs for such advertisements, potentially impacting their marketing strategies and drug prices.
Key points
Pharmaceutical companies will lose the ability to deduct direct-to-consumer drug advertising costs from their taxes.
This change applies to advertisements on radio, television, internet, social media, direct mail, and billboards.
Advertisements in journals and other periodicals will still be eligible for tax deductions.
article Official text account_balance Process page notifications_active Track this Bill
Status: Introduced
Civic Will
Checking votes...
I support
I oppose
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
Print number: 119_HR_3010
Sponsor: Rep. Murphy, Gregory F. [R-NC-3]
Process start date: 2025-04-24
System Note: Lustra is free, publicly auditable civic infrastructure — full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source—always verify them if you can.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

No Handouts for Drug Advertisements Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 119_HR_3010.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2025-04-24.

What are the main provisions?

Key points include:

  • Pharmaceutical companies will lose the ability to deduct direct-to-consumer drug advertising costs from their taxes.
  • This change applies to advertisements on radio, television, internet, social media, direct mail, and billboards.
  • Advertisements in journals and other periodicals will still be eligible for tax deductions.
What is the specific legal status?

The current status is Introduced.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Murphy, Gregory F. [R-NC-3].

What is the latest detailed status?

The latest detailed status is: Referred to the House Committee on Ways and Means.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-22.

What is the impact of this bill?

We don't know—that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge.

CATEGORIES

Taxes Health